According to the company, the patent protects composite particles that can generate free radicals or heat when excited by X-rays, and to the uses thereof in health, particularly human.
The inventive particles comprise an inorganic-based, and optionally organic-based, nucleus and can be activated in vivo, in order to label or alter cells, tissues or organs. The patent protection also relates to methods for the production of said particles, and to pharmaceutical or diagnostic compositions containing same, the company said.
Laurent Levy, president and CEO of Nanobiotix, said: “We are extremely pleased that our platform technology, nanoXray, is now patent-protected throughout the EU. We are hopeful that we will soon receive similar patent protection in the US as well.
“NanoXray is designed to allow the precise destruction of cancer cells via the controlled application of an outside-the-body energy source – a standard X-ray. Of course, protecting this intellectual property is key to long-term commercial success.”